These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. [Interpretation of the laboratory results concerning the protective effect of vaccines]. Berrón Morato S; Sanz Moreno JC; Martín García E; Salcedo Peláez C; Bermúdez Saugar MP; Vázquez Moreno JA Rev Esp Salud Publica; 1998; 72(5):431-3. PubMed ID: 9951337 [No Abstract] [Full Text] [Related]
43. A controlled field trial of a serogroup A meningococcal polysaccharide vaccine. Wahdan MH; Rizk F; el-Akkad AM; el-Ghoroury AA; Hablas R; Girgis NI; Amer A; Boctar W; Sippel JE; Gotschlich EC; Triau R; Sanborn WR; Cvjetanović B Bull World Health Organ; 1973 Jun; 48(6):667-73. PubMed ID: 4206451 [TBL] [Abstract][Full Text] [Related]
44. Control of meningococcal infection in the African meningitis belt by selective vaccination. Greenwood BM; Wali SS Lancet; 1980 Apr; 1(8171):729-32. PubMed ID: 6103155 [TBL] [Abstract][Full Text] [Related]
50. Further conquest of the meningococcus. Lepow ML; Gold R N Engl J Med; 1977 Sep; 297(13):721-2. PubMed ID: 408684 [No Abstract] [Full Text] [Related]
51. Protective efficacy of a bivalent (A + C) meningococcal vaccine during a cerebrospinal meningitis epidemic in Rwanda. Bosmans E; Vimont-Vicary P; Andre FE; Crooy PJ; Roelants P; Vandepitte J Ann Soc Belg Med Trop; 1980 Sep; 60(3):297-306. PubMed ID: 6788001 [No Abstract] [Full Text] [Related]
52. Changing epidemiology of meningococcal invasive disease in the Czech republic caused by new clone Neisseria meningitidis C:2a:P1.2(P1.5), ET-15/37. Krizova P; Musilek M Cent Eur J Public Health; 1995 Nov; 3(4):189-94. PubMed ID: 8903519 [TBL] [Abstract][Full Text] [Related]
53. Response of children to Neisseria meningitidis polysaccharide vaccines. Monto AS; Brandt BL; Artenstein MS J Infect Dis; 1973 Apr; 127(4):394-400. PubMed ID: 4632878 [No Abstract] [Full Text] [Related]
54. Meningococcal polysaccharide vaccines: recommendations of the Public Health Service Advisory Committee on Immunization Practices. Clin Pediatr (Phila); 1977 Sep; 16(9):764-5. PubMed ID: 408072 [No Abstract] [Full Text] [Related]
55. Meningitis vaccination in Auckland. Newman J N Z Med J; 1987 Oct; 100(833):636. PubMed ID: 3132658 [No Abstract] [Full Text] [Related]
56. Vaccination against meningococcal meningitis. Goldschneider I Conn Med; 1970 May; 34(5):335-9. PubMed ID: 5431940 [No Abstract] [Full Text] [Related]
57. [Antimeningococcal vaccination in member States of the Organization for Coordination and Cooperation in the Control of Major Epidemics]. Etienne J Prog Immunobiol Stand; 1971; 5():492-6. PubMed ID: 4633976 [No Abstract] [Full Text] [Related]
58. Who should be given meningococcal vaccine? Lancet; 1978 Dec; 2(8101):1185-6. PubMed ID: 82146 [No Abstract] [Full Text] [Related]
59. Effect of Neisseria meningitidis group A polysaccharide vaccine on nasopharyngeal carrier rates. Sivonen A J Infect; 1981 Sep; 3(3):266-72. PubMed ID: 6821094 [No Abstract] [Full Text] [Related]
60. The immunological responses observed in field studies in Africa with group A meningococcal vaccines. Gotschlich EC; Rey M; Etienne J; Sanborn WR; Triau R; Cvjetanović B Prog Immunobiol Stand; 1971; 5():485-91. PubMed ID: 4633975 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]